Blueprint Medicines Corporation
Clinical trials sponsored by Blueprint Medicines Corporation, explained in plain language.
A precision medicine company developing targeted therapies for cancer and rare diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill could tame stubborn hives that antihistamines Can't stop Results expected Dec 2026 (estimated)
- New drug aims to ease symptoms of rare mast cell disease Results expected Jun 2027 (estimated)
-
New pill could tame stubborn hives that antihistamines Can't stop
Disease control OngoingThis study tests an experimental drug called BLU-808 for people with chronic hives (urticaria) that don't get better with standard antihistamines. The drug works by blocking a protein called KIT, which may help control the allergic reaction causing the hives. About 105 adults wil…
Phase 2 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug aims to ease symptoms of rare mast cell disease
Symptom relief OngoingThis phase 2 study tests whether avapritinib, a targeted drug taken as a tablet, can reduce symptoms in people with indolent systemic mastocytosis whose symptoms are not well controlled by standard care. About 251 participants will receive either avapritinib or a placebo, and all…
Phase 2 • Sponsor: Blueprint Medicines Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC